June 22, 2015: WASHINGTON, D.C.âThe Association for the Accreditation of Human Research Protection Programs today announced that it has accredited seven more organizations, one of the largest groups in recent memory.
Three of the newly accredited organizations are in Asia, a region that is leading the international community in embracing AAHRPP accreditation. In fact, more than 10 percent of AAHRPP-accredited organizations are located there.
The newly accredited organizations are:
According to AAHRPP President and CEO Elyse I. Summers, the group is significant for its size and composition, both of which highlight “the growing, global recognition of the value of AAHRPP accreditation and the need for one standard worldwide to protect research participants.”
The newly accredited organizations include four highly respected U.S. academic institutions, a top-ranked university in China, and two of Taiwan’s leading hospitals.
“With these accreditations, we take another important step in extending AAHRPP’s high standards and advancing high-quality, ethical research around the globe,” Summers said. “We applaud the newly accredited-and all AAHRPP-accredited-organizations for their commitment to excellence and, above all, to safeguarding research participants.”
To earn AAHRPP accreditation, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to high standards for research. In today’s global, collaborative research enterprise, organizations increasingly rely on AAHRPP accreditation status to help identify trusted research partners.
To date, AAHRPP has accredited more than 210 organizations in 46 states, Canada, China, India, Mexico, Republic of Korea, Saudi Arabia, Singapore, Taiwan, and Thailand. All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 60 percent of U.S. research-intensive universities and over 65 percent of U.S. medical schools are either AAHRPP accredited or have begun the accreditation process. The National Institutes of Health, the world’s largest public funder of research, has earned accreditation, as has Pfizer, Inc., the largest industry sponsor of clinical research.
AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the U.S. government. To learn more, visit www.aahrpp.org.
###
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.